Abstract
Despite high basal NF-kappaB activity in acute myeloid leukemia (AML) cells, inhibiting NF-kappaB in these cells has little or no effect on inducing apoptosis. We previously showed that heme oxygenase-1 (HO-1) underlies this resistance of AML to tumor necrosis factor-induced apoptosis. Here, we describe a mechanism by which HO-1 is a silent antiapoptotic factor only revealed when NF-kappaB is inhibited, thus providing a secondary antiapoptotic mechanism to ensure AML cell survival and chemoresistance. We show that inhibition of NF-kappaB increased HO-1 expression in primary AML cells compared with that of nonmalignant cells. In addition, we observed this suppressed HO-1 level in AML cells compared with CD34(+) nonmalignant control cells. Using chromatin immunoprecipitation assay and small interfering RNA knockdown, we showed that the NF-kappaB subunits p50 and p65 control this suppression of HO-1 in AML cells. Finally, we showed that inhibition of HO-1 and NF-kappaB in combination significantly induced apoptosis in AML cells but not in noncancerous control cells. Thus, NF-kappaB inhibition combined with HO-1 inhibition potentially provides a novel therapeutic approach to treat chemotherapy-resistant forms of AML.
Original language | English |
---|---|
Pages (from-to) | 2973-2983 |
Number of pages | 11 |
Journal | Cancer Research |
Volume | 70 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Apr 2010 |
Keywords
- Acute Disease
- Antineoplastic Agents
- Apoptosis
- Chromatin Immunoprecipitation
- Enzyme Induction
- Heme Oxygenase-1
- Humans
- Leukemia, Myeloid
- NF-E2-Related Factor 2
- NF-kappa B
- NF-kappa B p50 Subunit
- Nitriles
- Promoter Regions, Genetic
- Reactive Oxygen Species
- Sulfones
- Transcription Factor RelA
- Tumor Cells, Cultured